Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma

Fineline Cube Mar 10, 2025

US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...

Company Deals

Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development

Fineline Cube Mar 10, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation...

Company Deals Medical Device

Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion

Fineline Cube Mar 10, 2025

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million...

Company Drug

AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease

Fineline Cube Mar 10, 2025

US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...

Company Deals

Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy

Fineline Cube Mar 10, 2025

India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of...

Company Drug

Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma

Fineline Cube Mar 10, 2025

US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...

Company

MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024

Fineline Cube Mar 10, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....

Company Medical Device

SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China

Fineline Cube Mar 10, 2025

Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound...

Company Drug

TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis

Fineline Cube Mar 10, 2025

Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...

Company Deals

Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments

Fineline Cube Mar 10, 2025

On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...

Company Drug

AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial

Fineline Cube Mar 10, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...

Company Deals

NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter

Fineline Cube Mar 9, 2025

NewCo is a new transaction model developed by Chinese innovative drug companies in response to...

Company

Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development

Fineline Cube Mar 9, 2025

Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s...

Company Deals

Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights

Fineline Cube Mar 7, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...

Company Drug

Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment

Fineline Cube Mar 7, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...

Company Drug

Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16

Fineline Cube Mar 7, 2025

China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...

Company Drug

Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease

Fineline Cube Mar 7, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Johnson & Johnson Terminate Phase III VENTURA Program for Aticaprant in adjunctive treatment of MDD

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced the termination of the Phase III...

Company Drug

Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production

Fineline Cube Mar 7, 2025

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million...

Company Drug

Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials

Fineline Cube Mar 7, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...

Posts pagination

1 … 253 254 255 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.